- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation
-
- Nakamura Yukinori
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Matsuguma Masafumi
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Tokunaga Yoshihiro
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Yamamoto Kaoru
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Tanaka Mayumi
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Tanaka Yoshinori
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Yujiri Toshiaki
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
-
- Tanizawa Yukio
- Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan
Bibliographic Information
- Other Title
-
- Successful Treatment of Behcet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation
Search this article
Description
<p>The coexistence of acute myeloid leukemia (AML) with Behçet's disease (BD) is rare. The optimum treatment for AML-associated BD has not been established. We herein report a patient with BD who developed AML with myelodysplasia-related changes. Induction chemotherapy caused complete remission of the AML but worsened the BD. Thereafter, AML was treated with azacitidine. The BD was steroid-dependent. Tacrolimus was added, which improved the BD. The patient underwent allogeneic hematopoietic stem cell transplantation (HSCT) and remains in complete remission for both diseases. Allogeneic HSCT was found to be a potent therapeutic option for AML-associated BD. In addition, azacitidine and tacrolimus were shown to be a suitable bridging regimen before HSCT. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 56 (10), 1199-1202, 2017
The Japanese Society of Internal Medicine